2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Recurrent Fallopian Tube Cancer: new trials by email Literature Review of Recurrent Fallopian Tube Cancer trials Research Report on Recurrent Fallopian Tube Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer paclitaxel, ganetespib, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 12 | 2013-10-09 | 2024-03-26 |
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin SJG-136, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 19 | 2010-07-01 | 2015-05-25 |
Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2)
Adnexal Diseases (2) · Carcinoma (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2)
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1) · Paclitaxel (1) · STA 9090 (1) · Taxes (1)
Fox Chase Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (2)
Gina Martina-Smaldone, MD (1) · Marta Crispens (1)
N01CM00100 (1), P30CA006927 (1)